The Demodex mite is a ubiquitous microscopic ectoparasite that colonises the pilosebaceous units on human skin, notably the eyelids, where it may contribute to conditions such as blepharitis and ...
Please provide your email address to receive an email when new articles are posted on . The “Mite Party” campaign is designed to raise awareness about Demodex blepharitis. Tarsus launched the campaign ...
Unique and memorable campaign intended to educate consumers about Demodex blepharitis and XDEMVY, the first and only FDA approved solution for the disease Demodex blepharitis impacts approximately 25 ...
Demodex blepharitis is a highly prevalent, yet often undiagnosed eyelid disease that impacts approximately 25 million eye care patients in the U.S. “We know that many patients struggle with eyelid ...
Tarsus to Host Eye Care Leaders Webcast on Unmet Needs in Demodex Blepharitis and Potential of TP-03
Interested parties may access the webcast here or at the events section of the Tarsus website. A replay will be available for a limited time at the same address. About TP-03TP-03 (lotilaner ophthalmic ...
Xdemvy is an eye drop prescribed for adults to treat Demodex blepharitis, an eyelid condition caused by mites. The recommended dosage is 1 drop in each eye twice per day for 6 weeks. While some people ...
Tarsus Pharma has a drug for Demodex blepharitis and multiple late-stage assets in its pipeline, including lotilaner for various formulations. The company has seen a 65% increase in stock value, with ...
IRVINE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback